Page last updated: 2024-10-15
marineosin b
Description
marineosin B: cytotoxic spiroaminal from a marine-derived actinomycete; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
marineosin B : A macrocycle isolated from a marine sediment-derived actinomycete, Streptomyces sp. A stereoisomer of marineosin A, it exhibits cytotoxicity against colon tumour cell lines. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (4)
Synonym |
marineosin b |
(1s,3s,3's,4as,15as)-3'-methoxy-3-methyl-5'-(1h-pyrrol-2-yl)-3',4,4',4a,5,6,7,8,9,10,11,15a-dodecahydro-3h-spiro[12,15-epiminocyclotrideca[c]pyran-1,2'-pyrrole] |
CHEBI:66677 |
Q27135297 |
Roles (2)
Role | Description |
metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (5)
Class | Description |
azaspiro compound | An azaspiro compound is a spiro compound in which at least one of the cyclic components is a nitrogen heterocyle. |
ether | An organooxygen compound with formula ROR, where R is not hydrogen. |
macrocycle | A cyclic compound containing nine or more atoms as part of the cyclic system. |
oxaspiro compound | A spiro compound in which at least one of the cyclic components is an oxygen heterocyle. |
pyrroles | An azole that includes only one N atom and no other heteroatom as a part of the aromatic skeleton. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 4 (80.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |